Phase 1 study to evaluate the safety of dasatinib in relapsed and refractory angioimmunoblastic T-cell lymphoma
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Dasatinib (Primary)
- Indications T-cell lymphoma
- Focus Adverse reactions
- 31 Jul 2018 Status changed from not yet recruiting to completed.
- 31 Jan 2017 New trial record